Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study
Background Ocrelizumab, a humanised anti-CD20 monoclonal, is a highly effective treatment for relapsing-remitting multiple sclerosis (RRMS). The long-term safety of B-cell depletion in RRMS, however, is uncertain and there are no data on dose reduction of ocrelizumab as a risk mitigation strategy. T...
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
BMJ Publishing Group
2024-06-01
|
| Saila: | BMJ Neurology Open |
| Sarrera elektronikoa: | https://neurologyopen.bmj.com/content/6/1/e000672.full |